Subscribe To
AZN / Should You Buy This Big Pharma Stock?
AZN News
By Proactive Investors
November 1, 2023
AstraZeneca inks gene editing deal that could end up costing it $2.5bn
AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) more_horizontal
By Reuters
November 1, 2023
AstraZeneca signs drug development deal with biotech Cellectis
AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee more_horizontal
By Zacks Investment Research
October 31, 2023
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day. more_horizontal
By Zacks Investment Research
October 30, 2023
Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact th more_horizontal
By The Motley Fool
October 28, 2023
3 No-Brainer Stocks to Buy for Under $100 Right Now
AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19. more_horizontal
By Market Watch
October 25, 2023
These healthcare stocks should come to life as boomers live their golden years
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healt more_horizontal
By Proactive Investors
October 24, 2023
Barclays and AstraZeneca up staff pay as Real Living Wage increases
Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on more_horizontal
By Market Watch
October 24, 2023
AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine
AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-adminis more_horizontal